"We Envision Growth Strategies Most Suited
to Your Business"

Multiple Sclerosis Drugs Market to Display 6.3% CAGR till 2028; Effective Oral MS Drugs Such as Tecfidera and Gilenya to Bolster Market Prospects: Fortune Business Insights™

June 08, 2021 | Healthcare

The global multiple sclerosis market size is projected to reach USD 41.99 billion by 2028 owing to the increasing use of monoclonal antibodies for treatment of MS, observes Fortune Business Insights™ in its report, titled “Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection (Intramuscular, Subcutaneous, and Intravenous) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast, 2021-2028”. As per the report, the value of the market was USD 26.05 billion in 2020 and the market is anticipated to register a CAGR of 6.3% from 2021 to 2028.

The COVID-19 pandemic has negatively impacted multiple sclerosis drugs industry as pharmaceutical industries were involved in manufacturing drugs and vaccines to curb the spread of the virus. Besides, the healthcare industry witnessed a major disruption in the supply chain due to the worldwide lockdown. This caused hindrance in transportation and logistics services, thus obstructing the market.

To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit:

FDA Accepted to Review New Drug ‘Ozanimod’ for Treating MS Patients

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted the review for ozanimod. This drug will be effective in the treatment of people suffering from relapsing forms of multiple sclerosis (RMS) in the US. Moreover, The European Medicines Agency (EMA) also accepted a Marketing Authorization Application for this drug to cure MS patients in the European Union. This drug is an oral, sphingosine 1-phosphate receptor modulator which binds with its S1P subtypes 1 (S1P1) and 5 (S1P5). It will further help in the reduction of lymphocyte migration in the central nervous system preventing immune-inflammatory indications in the patients.

To get a detailed report summary and research scope of this market, click here:


High Revenue Generated from Gilenya to Strengthen Market Position of Novartis AG

Biogen emerged as the leading player as the demand for its drug Tecfidera increased in the year 2020. Besides Novartis ranked second in the market owing to increased demand for Gilenya, since it is regarded as a more effective drug. In MRI scans, it showed that people who take Gilenya had very few active MS and it also slowed the process of disability which is associated with MS. Therefore, an increase in sales of Gilenya was reported. Its sales grew from $2.5 billion in 2014 to $3.3 billion in 2018, reported Forbes.

Extensive R&D Investment to Bolster the Multiple Sclerosis Drugs Market Growth

This market is rising dramatically owing to extensive research and investment. Pharmaceutical companies are focused on developing novel drugs and therapies to treat MS. For example, pharma firm Pipeline Therapeutics is performing clinical trials on PIPE-307, which will act as a selective M1 receptor to target MS antagonistically. Therefore, rising research activities will pave the way for many collaborations between pharmaceutical companies and research institutes, thus favoring the market.

Industry Development:

  • March 2020 – TG Therapeutics, Inc. announced the result of its phase 2 clinical trial experiments on ublituximab (TG-1101), which is an anti-CD20 monoclonal antibody that will help in treating multiple sclerosis.

A list of renowned Multiple Sclerosis Drugs providers operating in the global market:

  • Biogen (Massachusetts, U.S.)

  • Pfizer Inc. (New York, U.S.)

  • F. Hoffmann-La Roche Ltd. (Basel, Switzerland)

  • Novartis AG (Basel, Switzerland)

  • Merck & Co., Inc. (New Jersey, U.S.)

  • Sanofi (Paris, France)

  • Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)

  • Bristol-Myers Squibb Company (New York, U.S.)

  • Other Players

Further Report Findings:

  • Based on the route of administration of drugs, injections accounted for the maximum market share in the year 2020.  Meanwhile the oral drug administration was also popular due to the launch of effective and low cost tablet Zeposia for treatment of MS.

  • North America is set to dominate the multiple sclerosis drugs market share during the forecast period owing to the presence of several key players such as Pfizer, Merck, Roche Holdings AG, Amgen, Novartis and others in the region. The North America market share stood at USD 15.30 billion in 2020.

Table of Segmentation



Study Period


Base Year


Forecast Period


Historical Period



  Value (USD Billion)


Drug Class, Route of Administration, Distribution Channel, and Geography

By Drug Class


  • Immunomodulators   

  • Immunosuppressants 

  • Interferons     

  • Others

By Route of Administration


  • Oral

  •  Injection

    • Intramuscular

    • Subcutaneous

    • Intravenous

By Distribution Channel


  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

By Geography


  • North America

    • By Drug Class

    • By Route of Administration

    • By Distribution Channel

    • By Country

  • Europe

    • By Drug Class

    • By Route of Administration

    • By Distribution Channel

    • By Country/Sub-region

  • Asia Pacific

    • By Drug Class

    • By Route of Administration

    • By Distribution Channel

    • By Country/Sub-region

  • Latin America

    • By Drug Class

    • By Route of Administration

    • By Distribution Channel

    • By Country/Sub-region

  • Middle East & Africa

    • By Drug Class

    • By Route of Administration

    • By Distribution Channel

    • By Country/Sub-region

Multiple Sclerosis Drugs Market
  • PDF
  • 2020
  • 2017-2019
  • 160


  • 4850

Our Clients

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.